Table 1.
PLANETRA and PLANETAS studies: open-label extension up to 102 weeks
| PLANETRA
|
PLANETAS
|
||||
|---|---|---|---|---|---|
| Previous CT-P13 | Previous INX | Previous CT-P13 | Previous INX | ||
| No of pts | 158 | 144 | No of pts | 88 | 86 |
| Response at week 78 (% pts) | Response at week 78 (% pts) | ||||
| ACR20 | 71.7 | 78.2 | ASAS20 | 70.1 | 77.1 |
| ACR50 | 48.7 | 47.9 | ASAS40 | 57.5 | 51.8 |
| ACR70 | 25.0 | 29.6 | ASAS PR | 20.7 | 19.3 |
| Response at week 102 (% pts) | Response at week 102 (% pts) | ||||
| ACR20 | 71.7 | 71.8 | ASAS20 | 80.7 | 76.9 |
| ACR50 | 48.0 | 51.4 | ASAS40 | 63.9 | 61.5 |
| ACR70 | 24.3 | 26.1 | ASAS PR | 19.3 | 23.1 |
Abbreviations: pts, patients; ACR20/50/70, American College of Rheumatology 20/50/70; ASAS 20/40, Assessment of SpondyloArthritis International Society Response Criteria 20/40; ASAS PR, ASAS partial remission; INX, infliximab innovator; PLANETAS, Program evaluating the Autoimmune disease iNvEstigational drug cT-p13 in AS patients; PLANETRA, Program evaluating the Autoimmune disease iNvEstigational drug cT-p13 in RA patients.